Pretargeted radioimmunotherapy with Bi-213 in mice with CEA-expressing colon cancer xenografts
Pretargeted radioimmunotherapy (PRIT) with TF2, an anti-CEA x anti-HSG bispecific antibody, and 177Lu-labeled di-HSG-DOTA peptide IMP288, can delay tumor growth of CEA-expressing colon cancer xenografts. The therapeutic efficacy of PRIT may be improved by using alpha-emitting radionuclides. The aim of this study was to assess the potential of 213Bi for PRIT.
HESKAMP Sandra;
HERNANDEZ Reinier;
ESSLER Markus;
BRUCHERTSEIFER Frank;
MORGENSTERN Alfred;
OYEN Wim;
SEIDL C.;
MCBRIDE William;
GOLDENBERG David;
BOERMAN Otto;
2015-07-14
SOC NUCLEAR MEDICINE INC
JRC94668
0161-5505,
http://jnm.snmjournals.org/content/56/supplement_3.toc,
https://publications.jrc.ec.europa.eu/repository/handle/JRC94668,
Additional supporting files
| File name | Description | File type | |
|---|
